Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867357 · ClinicalTrials.gov registry record
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
A clinical trial, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- 60
- Enrollment target
NCT03867357 is a clinical trial that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 60 participants.
The verdict
NCT03867357 has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen deprivation therapy" or "ADT". Unfortunately, ADT also causes patients to be fatigued, weak and to loose muscle. This is often referred to as "sarcopenia" and it leads to falls, poor quality of life and higher risk of death. Currently, there is no treatment for sarcopenia because the investigators do not understand the mechanisms that cause it. The mitochondria is the part of the cells responsible for providing energy to muscles but to this date the investigators do not know if it is affected in prostate cancer patients with sarcopenia due to ADT. The overall goal of this proposal is to establish if the mitochondria is responsible for sarcopenia in patients with prostate cancer receiving ADT. The investigators will measure mitochondrial function, muscle mass and strength, and feelings of fatigue and quality of life in patients with prostate cancer before starting and after 6 months of ADT.
Interventions
- DRUG GnRH agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2023-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867357
The ClinicalTrials.gov registry entry for NCT03867357 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GnRH agonist is the first listed.
NCT03867357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03867357 about?
NCT03867357 is a clinical study titled "Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia". Prostate cancer (PCa) is the most common cancer among men and is even more common in the military and veteran population. For patients with advanced prostate cancer, the most common treatment includes lowering the levels of the hormone testosterone as much as possible. This is called "androgen depri...
What is the current status of trial NCT03867357?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2018-12-07. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT03867357?
The interventions under investigation include: GnRH agonist (DRUG).
Who is sponsoring clinical trial NCT03867357?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.